Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer

Yoneyama, T.; Οhyama, Chikara; Hatakeyama, Shingo; Narita, Shintaro; Habuchi, Tomonori; Koie, Takuya; Mori, Kazuyuki; Hidari, Kazuya I.P.J.; Yamaguchi, Mitsugu; Suzuki, Takashi; Tobisawa, Yuki

doi:10.1016/j.bbrc.2014.04.107

Cited by 75 publications

(79 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the clinical course of PCa patients varies and can be difficult to predict preoperatively. To date, several studies have reported a relationship between survival and pretreatment clinical features or molecular biomarkers, including Kattan nomogram [3], α2,3-linked sialylation as an additional terminal N-glycan on free PSA [4], and [-2] proPSA [5].…”

Section: Introductionmentioning

confidence: 99%

Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…We have also previously developed a magnetic bead-based S2,3PSA assay (Luminex method) that more accurately diagnoses early PCa than the conventional PSA test [19]. However, this method cannot measure benign S2,6PSA and does not have enough quantitative capability for clinical application.…”

Section: Introductionmentioning

confidence: 99%

An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis

Ishikawa

Yoneyama

Tobisawa

et al. 2017

IJMS

Self Cite

View full text Add to dashboard Cite

Abstract:The low specificity of the prostate-specific antigen (PSA) for early detection of prostate cancer (PCa) is a major issue worldwide. The aim of this study to examine whether the serum PCa-associated α2,3-linked sialyl N-glycan-carrying PSA (S2,3PSA) ratio measured by automated micro-total immunoassay systems (µTAS system) can be applied as a diagnostic marker of PCa. The µTAS system can utilize affinity-based separation involving noncovalent interaction between the immunocomplex of S2,3PSA and Maackia amurensis lectin to simultaneously determine concentrations of free PSA and S2,3PSA. To validate quantitative performance, both recombinant S2,3PSA and benign-associated α2,6-linked sialyl N-glycan-carrying PSA (S2,6PSA) purified from culture supernatant of PSA cDNA transiently-transfected Chinese hamster ovary (CHO)-K1 cells were used as standard protein. Between 2007 and 2016, fifty patients with biopsy-proven PCa were pair-matched for age and PSA levels, with the same number of benign prostatic hyperplasia (BPH) patients used to validate the diagnostic performance of serum S2,3PSA ratio. A recombinant S2,3PSA-and S2,6PSA-spiked sample was clearly discriminated by µTAS system. Limit of detection of S2,3PSA was 0.05 ng/mL and coefficient variation was less than 3.1%. The area under the curve (AUC) for detection of PCa for the S2,3PSA ratio (%S2,3PSA) with cutoff value 43.85% (AUC; 0.8340) was much superior to total PSA (AUC; 0.5062) using validation sample set. Although the present results are preliminary, the newly developed µTAS platform for measuring %S2,3PSA can achieve the required assay performance specifications for use in the practical and clinical setting and may improve the accuracy of PCa diagnosis. Additional validation studies are warranted.

show abstract

“…29 Additionally, it was similar in performance to the detection of Sia-2,3 PSA by fluorescent signals using a Luminex flowmetry system and anti-Sia-2,3 conformation IgG. 43 In this study, we showed that the simple use of lectin for analysis of changes to carbohydrate structures was possible by employing highly sensitive SPFS lectin immunoassay technology. These results indicate that the SPFS system is a promising technique for the validation of new biomarkers (particularly those utilizing structural changes in carbohydrates) with applications in clinical diagnostics.…”

Section: ■ Results and Discussionmentioning

confidence: 82%

High-Sensitivity Immunoassay with Surface Plasmon Field-Enhanced Fluorescence Spectroscopy Using a Plastic Sensor Chip: Application to Quantitative Analysis of Total Prostate-Specific Antigen and GalNAcβ1–4GlcNAc-Linked Prostate-Specific Antigen for Prostate Cancer Diagnosis

et al. 2015

View full text Add to dashboard Cite

A high-sensitivity immunoassay system with surface plasmon field-enhanced fluorescence spectrometry (SPFS) was constructed using a plastic sensor chip and then applied to the detection of total prostate-specific antigen (total PSA) and GalNAcβ1-4GlcNAc-linked prostate-specific antigen (LacdiNAc-PSA) in serum, to discriminate between prostate cancer (PC) and benign prostate hyperplasia (BPH). By using this automated SPFS immunoassay, the detection limit for total PSA in serum was as low as 0.04 pg/mL, and the dynamic range was estimated to be at least five digits. A two-step sandwich SPFS immunoassay for LacdiNAc-PSA was constructed using both the anti-PSA IgG antibody to capture PSA and Wisteria floribunda agglutinin (WFA) for the detection of LacdiNAc. The results of the LacdiNAc-PSA immunoassay with SPFS showed that the assay had a sensitivity of 20.0 pg/mL and permitted the specific distinction between PC and BPH within the PSA gray zone. These results suggested that high-sensitivity automated SPFS immunoassay systems might become a powerful tool for the diagnosis of PC and other diseases.

show abstract

Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer

Cited by 75 publications

References 22 publications

Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy

Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy

An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis

High-Sensitivity Immunoassay with Surface Plasmon Field-Enhanced Fluorescence Spectroscopy Using a Plastic Sensor Chip: Application to Quantitative Analysis of Total Prostate-Specific Antigen and GalNAcβ1–4GlcNAc-Linked Prostate-Specific Antigen for Prostate Cancer Diagnosis

Contact Info

Product

Resources

About